🔴 MDxHealth is trading 5.1% down in pre-market after suspending full-year 2026 revenue guidance

MDxHealth is trading 5.1% lower at $0.20 pre-market after suspending 2026 revenue guidance.

• Q3 revenue was about $22.7 million, flat year over year; full-year 2026 guidance: $110–115 million. Sales-force turnover after discontinuing Resolve mdx was cited.
• Lake Street downgraded MDxHealth to Hold from Buy and cut its price target to $0.50 from $3.00.
• October 16's 65.77% drop was followed by a $0.21 close; pre-market extends the reaction. No separate October 19 company announcement was identified.